Evotec Ag Ads (EVTCY) 10.9299 $EVTCY
Zacks.com featured highlights: HomeStreet, Horizon Global, Tata Motors, Evotec AG and Liberty Broadband
Zacks Equity Research - Zacks Investment Research - Thu Sep 08, 8:30AM CDT
Zacks.com featured highlights: HomeStreet, Horizon Global, Tata Motors, Evotec AG and Liberty Broadband
HMST: 25.18 (-0.61), LBRDA: 70.93 (+0.03), HZN: 18.92 (-0.20), TTM: 41.03 (-0.70)
7 Stocks with Recent Price Strength Set to Gain Further
Zacks Equity Research - Zacks Investment Research - Wed Sep 07, 8:18AM CDT
In the stock game, winning means reaching a higher price. So, how about looking for the current winners that have the potential to gain further?
HMST: 25.18 (-0.61), LBRDA: 70.93 (+0.03), DCO: 22.51 (-0.51), HZN: 18.92 (-0.20), HNRG: 8.26 (+0.09), TTM: 41.03 (-0.70)
AstraZeneca Asthma Drug Symbicort Positive in Safety Trial
Zacks Equity Research - Zacks Investment Research - Thu Sep 01, 9:21AM CDT
AstraZeneca PLC (AZN) announced positive results from a safety study on Symbicort inhaler in patients suffering from asthma compared to budesonide alone.
BSTC: 45.26 (+1.22), AZN: 33.97 (-0.31), OHRP: 2.81 (+0.03)
Evotec/Spero Deal Extended For Gram-negative Bacteria
Zacks Equity Research - Zacks Investment Research - Wed Dec 16, 12:20PM CST
Evotec (EVTCY) extended its collaboration agreement with Spero Therapeutics to develop new and ground-breaking therapeutics for Gram-negative bacteria.
ACHN: 8.69 (+0.25), ANIK: 46.92 (-1.07), CORT: 6.49 (unch)
Sanofi Inks Deals, Diabetes and Immuno-Oncology in Focus
Zacks Equity Research - Zacks Investment Research - Mon Aug 10, 2:15PM CDT
Sanofi (SNY) strikes agreements with Evotec and Apeiron Biologics in the area of diabetes and immuno-oncology, respectively.
GILD: 81.37 (-0.15), SNY: 38.35 (-0.22), REGN: 410.39 (+2.38)
Evotec Signs New Deal for Addictive Disorder Therapies - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jan 20, 5:12PM CST
Evotec AG (EVTCY) entered into a research collaboration agreement with C4X Discovery Holdings plc for the development of Orexin-1 selective inhibitors.
JNJ: 118.81 (-0.65), ENDP: 23.39 (+3.13), SNY: 38.35 (-0.22)
Zacks.com featured highlights: HomeStreet, Horizon Global, Tata Motors, Evotec AG and Liberty Broadband
Zacks Equity Research - Zacks Investment Research - Thu Sep 08, 8:30AM CDT
Zacks.com featured highlights: HomeStreet, Horizon Global, Tata Motors, Evotec AG and Liberty Broadband
HMST: 25.18 (-0.61), LBRDA: 70.93 (+0.03), HZN: 18.92 (-0.20), TTM: 41.03 (-0.70)
7 Stocks with Recent Price Strength Set to Gain Further
Zacks Equity Research - Zacks Investment Research - Wed Sep 07, 8:18AM CDT
In the stock game, winning means reaching a higher price. So, how about looking for the current winners that have the potential to gain further?
HMST: 25.18 (-0.61), LBRDA: 70.93 (+0.03), DCO: 22.51 (-0.51), HZN: 18.92 (-0.20), HNRG: 8.26 (+0.09), TTM: 41.03 (-0.70)
AstraZeneca Asthma Drug Symbicort Positive in Safety Trial
Zacks Equity Research - Zacks Investment Research - Thu Sep 01, 9:21AM CDT
AstraZeneca PLC (AZN) announced positive results from a safety study on Symbicort inhaler in patients suffering from asthma compared to budesonide alone.
BSTC: 45.26 (+1.22), AZN: 33.97 (-0.31), OHRP: 2.81 (+0.03)
Evotec/Spero Deal Extended For Gram-negative Bacteria
Zacks Equity Research - Zacks Investment Research - Wed Dec 16, 12:20PM CST
Evotec (EVTCY) extended its collaboration agreement with Spero Therapeutics to develop new and ground-breaking therapeutics for Gram-negative bacteria.
ACHN: 8.69 (+0.25), ANIK: 46.92 (-1.07), CORT: 6.49 (unch)
Sanofi Inks Deals, Diabetes and Immuno-Oncology in Focus
Zacks Equity Research - Zacks Investment Research - Mon Aug 10, 2:15PM CDT
Sanofi (SNY) strikes agreements with Evotec and Apeiron Biologics in the area of diabetes and immuno-oncology, respectively.
GILD: 81.37 (-0.15), SNY: 38.35 (-0.22), REGN: 410.39 (+2.38)
Evotec Signs New Deal for Addictive Disorder Therapies - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jan 20, 5:12PM CST
Evotec AG (EVTCY) entered into a research collaboration agreement with C4X Discovery Holdings plc for the development of Orexin-1 selective inhibitors.
JNJ: 118.81 (-0.65), ENDP: 23.39 (+3.13), SNY: 38.35 (-0.22)
